{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:32:59Z","timestamp":1759883579385,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.omtm.2025.101439","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:26:35Z","timestamp":1740108395000},"page":"101439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical efficacy of a modified gamma-globin lentivirus gene therapy in Berkeley sickle cell anemia mice and human xenograft models"],"prefix":"10.1016","volume":"33","author":[{"given":"Archana","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin M.","family":"Pillis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Felker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengna","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwabukola T.","family":"Gbotosho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Sieling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Shadid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-2108","authenticated-orcid":false,"given":"Punam","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101439_bib1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101439_bib2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/180326a0","article-title":"Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin","volume":"180","author":"Ingram","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101439_bib3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101439_bib4","doi-asserted-by":"crossref","first-page":"8280","DOI":"10.1016\/S0021-9258(17)39467-X","article-title":"Refined crystal structure of deoxyhemoglobin S. II. Molecular interactions in the crystal","volume":"260","author":"Padlan","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101439_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev.ge.06.120172.000403","article-title":"The molecular basis of hemoglobin disease","volume":"6","author":"Stamatoyannopoulos","year":"1972","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.omtm.2025.101439_bib6","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00431-020-03656-x","article-title":"Acute care utilization in pediatric sickle cell disease and sickle cell trait in the USA: prevalence, temporal trends, and cost","volume":"179","author":"Peterson","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.omtm.2025.101439_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.omtm.2018.10.014","article-title":"Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling \u03b2AS3 Globin for Gene Therapy for Sickle Cell Disease","volume":"11","author":"Poletti","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101439_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4103\/0971-6866.116128","article-title":"Comparison of in-vitro and in-vivo response to fetal hemoglobin production and \u03b3-mRNA expression by hydroxyurea in Hemoglobinopathies","volume":"19","author":"Italia","year":"2013","journal-title":"Indian J. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101439_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI133856","article-title":"Are genetic approaches still needed to cure sickle cell disease?","volume":"130","author":"Brodsky","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtm.2025.101439_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bjh.16437","article-title":"Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?","volume":"189","author":"Leonard","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtm.2025.101439_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101439_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/2040620716653729","article-title":"The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges","volume":"7","author":"Goodman","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.omtm.2025.101439_bib13","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"CLIMB SCD-121 Study Group. Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101439_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101439_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41591-021-01554-9","article-title":"Lentiviral globin gene therapy with reduced-intensity conditioning in adults with beta-thalassemia: a phase 1 trial","volume":"28","author":"Boulad","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101439_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101439_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101439_bib18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101439_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101439_bib20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101439_bib21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101439_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41587-021-01127-8","article-title":"First gene therapy for adrenoleukodystrophy","volume":"39","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101439_bib23","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2009-01-201863","article-title":"A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction","volume":"114","author":"Perumbeti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101439_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/mt.2009.183","article-title":"Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region","volume":"17","author":"Arumugam","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101439_bib25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo","volume":"22","author":"Cesana","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101439_bib26","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.ymthe.2022.02.028","article-title":"Globin vector regulatory elements are active in early hematopoietic progenitor cells","volume":"30","author":"Cabriolu","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101439_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/hum.2010.233","article-title":"The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors","volume":"22","author":"Emery","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101439_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01639-17","article-title":"Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential","volume":"92","author":"Goodman","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101439_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00062752-199704020-00003","article-title":"Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias","volume":"4","author":"P\u00e1szty","year":"1997","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.omtm.2025.101439_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.stemcr.2014.12.005","article-title":"Nonirradiated NOD, B6.SCID Il2r\u03b3-\/- Kit(W41\/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells","volume":"4","author":"McIntosh","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.omtm.2025.101439_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306719","article-title":"Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathies","volume":"19","author":"Shadid","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101439_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3233\/CH-189012","article-title":"Inflammation in sickle cell disease","volume":"68","author":"Conran","year":"2018","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"10.1016\/j.omtm.2025.101439_bib33","article-title":"Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry","volume":"153","author":"Rab","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omtm.2025.101439_bib34","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood.V54.4.872.872","article-title":"Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures","volume":"54","author":"Hoover","year":"1979","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101439_bib35","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2005-07-2839","article-title":"Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease","volume":"107","author":"Manci","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101439_bib36","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ajpath.2012.07.034","article-title":"Splenic morphological changes are accompanied by altered baseline immunity in a mouse model of sickle-cell disease","volume":"181","author":"Szczepanek","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtm.2025.101439_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101439_bib38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101439_bib39","doi-asserted-by":"crossref","first-page":"14380","DOI":"10.1073\/pnas.212507099","article-title":"Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells","volume":"99","author":"Imren","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101439_bib40","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/mt.2009.89","article-title":"Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR","volume":"17","author":"Urbinati","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101439_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1472-6750-9-13","article-title":"Incorporating double copies of a chromatin insulator into lentiviral vectors results in less viral integrants","volume":"9","author":"Nielsen","year":"2009","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.omtm.2025.101439_bib42","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/mt.2011.20","article-title":"Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat \u03b2-thalassemia","volume":"19","author":"Ronen","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101439_bib43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nbt.3062","article-title":"Genomic discovery of potent chromatin insulators for human gene therapy","volume":"33","author":"Liu","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101439_bib44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101439_bib45","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101439_bib46","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/blood-2004-04-1427","article-title":"Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector","volume":"104","author":"Puthenveetil","year":"2004","journal-title":"Blood"}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:47:43Z","timestamp":1759862863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125000348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2329050125000348"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101439","relation":{},"ISSN":["2329-0501"],"issn-type":[{"type":"print","value":"2329-0501"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical efficacy of a modified gamma-globin lentivirus gene therapy in Berkeley sickle cell anemia mice and human xenograft models","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101439"}}